1,8-bis[(3-hydroxypropyl)amino]anthracene-9,10-dione | 99108-01-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 蒽
• 英文名称: 1,8-bis[(3-hydroxypropyl)amino]anthracene-9,10-dione
• 英文别名: 1,8-bis-(3-hydroxy-propylamino)-anthraquinone；1,8-bis(3-hydroxypropylamino)anthracene-9,10-dione
• CAS: 99108-01-7
• 化学式: C₂₀H₂₂N₂O₄
• 分子量: 354.406
• InChiKey: OQSYYTSWSXEJHW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  26
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  98.7
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1,8-bis[(3-hydroxypropyl)amino]anthracene-9,10-dione 在 三乙胺 作用下， 生成 3-{[8-({3-[(2-methylprop-2-enoyl)oxy]propyl}amino)-9,10-dioxoanthracen-1-yl]amino}propyl 2-methylprop-2-enoate
  参考文献：
  名称：

  Curable Ink Composition

  摘要：

  提供的是一种可治愈的油墨组合物，特别是一种可治愈的喷墨油墨组合物。该油墨组合物具有染料单体、载体单体和引发剂。染料单体具有一种色团基团，该色团基团与至少一个可聚合的官能团共价键合，并且按照油墨组合物的总重量计算，其含量为1.0重量％或更多。载体单体具有至少一个可聚合的官能团，并且按照油墨组合物的总重量计算，其含量为50重量％或更多。该油墨组合物适用于辐射固化，如紫外线固化，并具有良好的固化性能或耐光性能。

  公开号：

  US20220145109A1
• 作为产物：
  描述：

  1,8-二氯蒽醌 、 3-氨基-1-丙醇 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.5h， 以71%的产率得到1,8-bis[(3-hydroxypropyl)amino]anthracene-9,10-dione
  参考文献：
  名称：

  1,8-二氨基蒽醌衍生物的合成及其抗肿瘤活性。

  摘要：

  继续我们对细胞毒性物质的正在进行的研究，基于拟议的生物活性氨基构象，已经合成了一系列区域异构的二取代氨基蒽醌（DAAQ）衍生物作为细胞毒性活性。评估位于蒽醌环系统位置1和8的蒽醌侧链中氨基取代的生物活性。该研究的目的是确定蒽醌家族的成员是否可以用作增强抗癌剂在大鼠神经胶质瘤C6细胞，人肝癌G2细胞和2.2.15细胞中的生长抑制作用的辅助剂。已报道了该化合物的体外细胞毒性数据，并已发现一些结构-活性关系的迹象。发现许多化合物对这三种细胞系的增殖具有良好的细胞毒性。

  DOI：

  10.1248/cpb.53.1136

文献信息

• Quencher compositions comprising anthraquinone moieties
  申请人：Lomholt Christian

  公开号：US20050227254A1

  公开（公告）日：2005-10-13

  The present invention provides novel quencher composition comprising anthraquinone quencher moieties. The anthraquinone quencher moieties are useful as quencher labels when attached to biomolecules such as natural or modified polynucleotides, oligonucleotides, nucleosides, nucleotides, carbohydrates and peptides. For example, polynucleotides can be labeled at the 3′ terminus with fluorescence quencher solid support compositions, and polynucleotides can be labeled at internally or at the 5′ terminus. The detectable probes may have a format like molecular beacons, scorpion probes, sunrise probes, conformationally assisted probes and TaqMan probes.

  本发明提供了一种新型猝灭剂组合物，包括蒽醌猝灭剂基团。当连接到生物分子（如天然或改性多聚核苷酸、寡核苷酸、核苷、核苷酸、碳水化合物和肽）时，蒽醌猝灭剂基团可用作猝灭剂标记。例如，多聚核苷酸可在3'端标记荧光猝灭剂固相支持组合物，也可在内部或5'端标记多聚核苷酸。可检测的探针可能具有类似分子信标、蝎子探针、日出探针、构象辅助探针和TaqMan探针的格式。
• Anthracene derivatives as anti-cancer agents
  申请人：——

  公开号：US20030130272A1

  公开（公告）日：2003-07-10

  Use of compound of Formula (I): at least one of R 1 , R 2 , R 5 and R 6 is a group —AB and the others are independently selected from hydrogen, hydroxy, alkoxy or acyloxy, a group —AB a group -amino-(R 7 ) n X—Y wherein R 7 is a divalent organic radical and n is 0 or 1; R 3 and R 4 are independently oxo, hydroxy or hydrogen; the or each A is independently a spacer group of formula -amino-(R 7 ) n —X— which is bonded to the anthracene ring via the amino group nitrogen and to B via —X—, X is independently selected from O, NH and C(O); B is an amino acid residue or a peptide group or isostere thereof and Y is hydrogen or a capping group, or a physiologically acceptable derivative of such compound for the manufacture of a medicament for the treatment of cancers or microbial infections having cells exhibiting topoisomerase I activity characterised in that the group -amino-(R 7 ) n —X— incorporates an optionally substituted heterocyclic ring directly attached to the anthroquinone ring through an amino nitrogen in the heterocycclic ring, or an optionally substituted heterocyclic or carbocyclic ring that is spaced from the anthraquinone ring by no more than an amino nitrogen and up to four carbon atoms.

  使用化合物Formula (I)：R1、R2、R5和R6中至少一个是群组—AB，其余的可独立选择氢、羟基、烷氧基或酰氧基，一个群组—AB，一个群组-amino-(R7)nX—Y，其中R7是二价有机基团，n为0或1；R3和R4独立地为氧、羟基或氢；每个A独立地为配体基团，其公式为-amino-(R7)n—X—，通过氨基氮与蒽环键合，并通过—X—与B键合，X独立地选择自O、NH和C(O)；B为氨基酸残基或肽基团或其异构体，Y为氢或一个封端基团，或其生理可接受的衍生物，用于制造治疗癌症或微生物感染的药物，这些疾病的细胞具有拓扑异构酶I活性，其特点在于群组-amino-(R7)n—X—包含一个可选择取代的杂环直接通过杂环环中的氨基氮与蒽醌环键合，或通过不超过一个氨基氮和最多四个碳原子与蒽醌环相距的可选择取代的杂环或碳环。
• Potential Antitumor Agents, XV. Anthraquinone Derivatives
  作者：Aldo Andreani、Mirella Rambaldi、Daniela Bonazzi、Giovanna Lelli、Rosaria Bossa、Iraklis Galatulas

  DOI：10.1002/ardp.19853180914

  日期：——

  The synthesis of hydroxyalkylamino derivatives from 1,8‐dichloroanthraquinone and succinic esters from hydroxyanthraquinones is reported. The esters 10 and 12 show significant antitumor activity but without improvement in comparison to the activity of a previously described analogue.

  报道了由 1,8-二氯蒽醌合成羟烷基氨基衍生物和由羟基蒽醌合成琥珀酸酯。酯10和12显示出显着的抗肿瘤活性，但与先前描述的类似物的活性相比没有改进。
• [EN] ANTHRACENE DERIVATIVES AS ANTI-CANCER AGENTS<br/>[FR] DERIVES D'ANTHRACENE UTILISES COMME AGENTS ANTICANCEREUX (III)
  申请人：BTG INT LTD

  公开号：WO2001044190A1

  公开（公告）日：2001-06-21

  Use of compound of Formula (I): at least one of R?1, R2, R5 and R6¿ is a group -AB and the others are independently selected from hydrogen, hydroxy, alkoxy or acyloxy, a group -AB a group -amino-(R7)nX-Y wherein R7 is a divalent organic radical and n is 0 or 1; R?3 and R4¿ are independently oxo, hydroxy or hydrogen; the or each A is independently a spacer group of formula -amino-(R7)n-X- which is bonded to the anthracene ring via the amino group nitrogen and to B via -X-, X is independently selected from O, NH and C(O); B is an amino acid residue or a peptide group or isostere thereof and Y is hydrogen or a capping group, or a physiologically acceptable derivative of such compound for the manufacture of a medicament for the treatment of cancers or microbial infections having cells exhibiting topoisomerase I activity characterised in that the group -amino-(R7)n-X- incorporates an optionally substituted heterocyclic ring directly attached to the anthroquinone ring through an amino nitrogen in the heterocycclic ring, or an optionally substituted heterocyclic or carbocyclic ring that is spaced from the anthraquinone ring by no more than an amino nitrogen and up to four carbon atoms.

  化合物的公式（I）的使用：至少R?1，R2，R5和R6¿中的一个是-AB基团，其余的独立选择自氢，羟基，烷氧基或酰氧基，一个-AB基团一个-氨基-（R7）nX-Y基团，其中R7是二价有机基团，n为0或1; R?3和R4¿独立地为氧，羟基或氢; 每个A独立地为公式-amino-（R7）n-X-的间隔基团，通过氨基氮与蒽环连接，并通过-X-与B连接，X独立选择自O，NH和C（O）; B是氨基酸残基或肽基团或其同分异构体，Y是氢或顶端基团，或其生理上可接受的衍生物，用于制造用于治疗细胞表现出拓扑异构酶I活性的癌症或微生物感染的药物，其特征在于-氨基-（R7）n-X-基团是直接通过杂环环上的氨基氮与蒽醌环结合的可选取代杂环环，或者是与蒽醌环之间最多一个氨基氮和四个碳原子的间隔的可选取代杂环或碳环。
• Novel methods for quantification of microRNAs and small interfering RNAs
  申请人：Jacobsen Nana

  公开号：US20050272075A1

  公开（公告）日：2005-12-08

  The invention relates to ribonucleic acids, probes and methods for detection, quantification as well as monitoring the expression of mature microRNAs and small interfering RNAs (siRNAs). The invention furthermore relates to methods for monitoring the expression of other non-coding RNAs, mRNA splice variants, as well as detecting and quantifying RNA editing, allelic variants of single transcripts, mutations, deletions, or duplications of particular exons in transcripts, e.g., alterations associated with human disease such as cancer. The invention furthermore relates to methods for detection, quantification as well as monitoring the expression of deoxy nucleic acids.

  本发明涉及核糖核酸、探针和检测、定量以及监测成熟微小RNA和小干扰RNA（siRNA）表达的方法。此外，本发明还涉及监测其他非编码RNA、mRNA剪接变体的表达，以及检测和定量RNA编辑、单个转录本的等位变体、突变、缺失或重复特定外显子的方法，例如与人类疾病如癌症相关的改变。此外，本发明还涉及检测、定量以及监测脱氧核糖核酸的表达的方法。